Trials
2 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Polycythemia Vera
- Main trialPhase 2/3
- “This clinical trial is a Phase 2/3 study that will determine the recommended dose and dose regimen of AG-236 and evaluate the efficacy, safety, and pharmacokinetics of AG-236 in polycythemia vera (PV) by testing how well AG-236 works compared to placebo to increase the number of subjects with no phlebotomy and absence of phlebotomy eligibility over a 13-week period. In addition, the long-term effect of AG-236 on efficacy and safety will be explored in an open-label extension portion.”In the company’s words, NCT07859423 on ClinicalTrials.gov
Other drugs for Polycythemia Vera
- Givinostat HydrochlorideItalfarmaco · Phase 3
- RusfertideProtagonist Therapeutics, Inc. · Phase 3
- BomedemstatMerck & Co. · Phase 3
- Ropeginterferon alfa-2bPharmaEssentia · Phase 3
- FlonoltinibChengdu Zenitar Biomedical Technology Co., Ltd · Phase 2
- DISC-3405Disc Medicine, Inc · Phase 2
Coming up1
- Aug 2030Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Not yet recruiting | Aug 2030 | A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera | |
| Phase 1Active, not recruiting | 11 Feb 2026 | A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026